Paul Hastings LLP has extensive expertise in IPOs for common stock shares, acting on behalf of issuers and underwriters mainly focused on the oil and gas, chemicals energy transition, and infrastructure spheres. The team routinely represents investment banks, public companies, and venture capital funds, with New York-based Frank Lopez heading the firm’s global securities and capital markets practice. Also operating out of New York, Colin Diamond has vast knowledge in registered equity offerings, private placements, and convertible bond offerings, with Seo Salimi standing out for his. work in cross-border capital market transactions in the life sciences field.
Legal 500 Editorial commentary
Phone
(212) 318-6030
Email
Profile

Profile

Work Department

Partner, Corporate Department

Position

Seo Salimi is a partner and the Co-Head of Equity Capital Markets and Co-Chair of the Corporate Life Science Group of Paul Hastings and is based in the firm's New York office. His practice focuses on representing life science companies and investment banks in public and private capital markets transactions, such as initial public offerings, follow-on offerings, at-the-market transactions, and private placements. Mr. Salimi has extensive experience in cross-border financing transactions, representing issuers and investment banks in complex dual listings and cross border initial public offerings and follow-on offerings. Mr. Salimi is a trusted advisor to both public and private companies in their capital raising strategy and ongoing corporate matters, including SEC compliance and corporate governance.

Mr. Salimi has been recognized as a “Next Generation Partner” for Capital Markets: Equity by The Legal 500 US, where clients note he is “committed, hard-working and driven; his ability to manage across his team, both up and down, as well as his interactions with counsel from the other party makes [Mr. Salimi] invaluable.” In 2020, Mr. Salimi was nominated for the “US Rising Star – Financial & Corporate” award by LMG Life Sciences.

Education

  • University of Southern California Gould School of Law, J.D. (top of class), 2004
  • University of California, Irvine, B.A., 2001

Content supplied by Paul Hastings LLP

Key clients

  • Goldman Sachs
  • J.P. Morgan Securities
  • Morgan Stanley
  • Jefferies
  • Barclays
  • BofA Securities
  • Piper Sandler and Co.
  • TD Securities (USA) LLC
  • Guggenheim Securities Inc.
  • Leerink Partners, LLC
  • Cantor Fitzgerald & Co.
  • Oppenheimer & Co.
  • Wells Fargo
  • Viking Therapeutics
  • Kyverna Therapeutics
  • Genesis Energy
  • SilverBox Corp IV
  • Innovex Downhole Solutions, Inc.
  • Kayne Anderson BDC, Inc.
  • Varonis Systems, Inc.
  • Amentum
  • Heidrick & Struggles
  • Moody’s

Work highlights

Represented Viking Therapeutics, Inc., as issuer, in its USD $632.5 million follow-on public offering of its common stock.
Represented Kyverna Therapeutics, Inc., as issuer, in its upsized initial USD $366.9 million public offering.
Advised Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen, and Stifel as joint bookrunning managers in connection with Syndax Pharmaceuticals’ USD $230 million public offering.